The science of cancer stem cells is still evolving, and despite the many unknowns, holds significant promise for the next phase of oncology therapeutics. Advances in understanding the origin of cancer stem cells, and their role in tumor development and metastasis are shedding new light on the challenge of treatment resistance and disease recurrence. At CHI’s Targeting Cancer Stem Cell symposium, the following commercial and academic organizations will come together to discuss promising new therapeutics for oncology:
Alligator Bioscience AB, American Laboratory, Amgen Inc., Barclays Capital, Bionomics Inc., Boston Biomedical Inc., Cedars Sinai Medical Center, Celera Corp., Cellerant Therapeutics Inc., CureMeta LLC, Daiichi Sankyo Co Ltd, Dainippon Sumitomo Pharma Co Ltd, Eli Lilly & Co., EMD Serono, ETH Zurich, Evgen Ltd, Fluidigm Corp., Genentech Inc., Illumina, IMEC, Janssen R&D LLC, John Wayne Cancer Institute, JSR Life Sciences Corp., Kaiser Permanente, Latvian Biomedical Research & Study Center, MacroGenics Inc., McMaster University, Miltenyi Biotec GmbH, Mount Sinai School of Medicine, Novartis Institutes for BioMedical Research, OncoMed Pharmaceuticals Inc., Ono Pharma USA, Onyx Pharmaceuticals Inc., Oregon Health & Science University, Osaka University, Panagene, Personal Genomics Institute, Pfizer Inc., PLUS Diagnostics, Pontificia University Catolica de Chile, Quanticel Pharmaceuticals, Roche Molecular Systems Inc., Sears Capital Management, Sillman Consulting, Southern Illinois University, SRI International, STMicroelectronics, Summit Pharmaceuticals Intl Corp., TetraQ, UK Trade & Investment, University of Auckland, University of California Los Angeles, University of California Los Angeles, University of California San Diego, University of Michigan, University of Minnesota Twin Cities, University of Texas Dallas, University of Ulster, University of Virginia, University of Wisconsin Madison, Verastem Inc., Vertex Pharmaceuticals Inc.
Full details on this symposium can be viewed at TriConference.com/.
As part of the Molecular Med TRI-CON 2013, attendees have access to 5 symposia, 16 short courses, and 19 core programs around 5 scientific channels: diagnostics, therapeutics, clinical, informatics, and cancer. The event attracts than 3,000 attendees and provides attendees an opportunity to interact with each other in the shared exhibit/poster hall, plenary keynotes and social functions.
To inquire about sponsoring and/or exhibiting, contact Jon Stroup, 781-972-5483, jstroup[.]healthtech.com.
Writers and editors are encouraged to attend. To request a press pass, contact Lisa Scimemi lscimemi[.]healthtech.com.
About Cambridge Healthtech Institute (CHI)
Cambridge Healthtech Institute (healthtech.com) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Barnett Educational Services, Cambridge Meeting Planners and CHI’s Media Group, which includes news websites and e-newsletters including Bio-IT World and eCliniqua. Founded in 1992, CHI strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments.